Charles River Laboratories International, Inc. (CRL) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $2.46, which reflected a 17.4% decrease year over year. However, the metric surpassed the Zacks Consensus Estimate by 2.9%.On a GAAP basis, earnings declined 0.8% year over year to $3.62 per share. The year-over-year decrease in GAAP earnings was primarily due to lower revenues and operating income.For the full year, adjusted EPS was $10.67 per share, down 4% from the year-ago period’s leve ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED December 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Cha ...

Charles River Laboratories International, Inc. (CRL) is likely to grow in the coming quarters, backed by the strong prospects of the RMS (Research Models and Services) segment. Presently, the company is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide. Stable solvency is an added upside.However, headwinds related to foreign exchange fluctuations and competitive pressure remain concerning for CRL’s operations.In the past year, this Za ...

Wall Street analysts expect Charles River Laboratories (CRL) to post quarterly earnings of $2.39 per share in its upcoming report, which indicates a year-over-year decline of 19.8%. Revenues are expected to be $985.69 million, down 10.4% from the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a co ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report fourth-quarter and full-year 2023 results on Feb 14, before market open.In the last reported quarter, the company’s adjusted earnings per share of $2.72 surpassed the Zacks Consensus Estimate by 15.7%. Earnings surpassed estimates in each of the trailing four quarters, the average beat being 8.43%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayThe Research Models and Services (RMS) segment i ...

Charles River International Laboratories, Inc. (CRL) recently launched Endosafe Trillium rCR cartridges, which combine its hallmark Endosafe cartridge technology with recombinant cascade reagent (rCR). The latest launch expanded the company’s robust bacterial endotoxin testing (BET) portfolio with a new animal-free testing solution.The recent development will bolster the Charles River Microbial Solutions business.More on the LaunchThe latest launch, which expands Charles River's existing Trillium rCR vial p ...

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 14th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.cri ...

Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chairman, President & Chief Executive Officer Flavia Pease - Executive Vice President & Chief Financial Officer Conference Call Participants Eric Coldwell - Baird Elizabeth Anderson - Evercore Derik De Bruin - Bank of America Casey Woodring - JPMorgan Patrick Donnelly - Citi Dave Windley - Jefferies Justin B ...

| --- | --- | --- | --- | |----------------------|--------|-------|--------------| | ($ in millions) | 3Q23 | 3Q22 | 2023 Outlook | | Free cash flow (FCF) | $139.5 | $60.4 | $340-$360 | | Capex | $65.9 | $72.4 | $330-$340 | | Depreciation | $44.6 | $39.1 | ~$180 | | Amortization (1) | $34.2 | $35.5 | $135-$140 | ─ Continue to take a disciplined approach to managing capital deployment and are committed to aligning capacity and capital investments with current demand trends | --- | --- | --- | |-------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File No. 001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jur ...